In vitro

PathogenDx, Inc. Receives FDA Emergency Use Authorization for Microarray-based COVID-19 Test

Retrieved on: 
Monday, April 26, 2021
Medicine, Clinical Laboratory Improvement Amendments, Healthcare in the United States, In vitro, Medical laboratory, Microarray, Natural sciences, Health, DiaSorin, Molecular diagnostics

Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C.

Key Points: 
  • Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C.
  • 263a, that meet requirements to perform high complexity tests.\nDetectX-Rv offers high-throughput capability and can process controls and 94 samples in a single run.\n"The entire PathogenDx team is committed to applying our deep knowledge of clinical diagnostics technology to develop accurate tests that can help contain the COVID-19 pandemic," said Milan Patel, Co-Founder and CEO of PathogenDx.\nThe FDA is responsible for regulating medical devices used to diagnose, prevent and treat COVID-19.
  • 360bbb- 3(b)(1), unless the declaration is terminated or authorization is revoked sooner.\nHeadquartered in Scottsdale, Arizona, PathogenDx\'s mission is to become the new standard in DNA-based testing through widespread adoption of its advanced microarray testing platform for the in vitro diagnostics, food and agricultural industries.
  • For more information on how you can utilize this simple, powerful and inexpensive platform, visit www.pathogendx.com .\n'

Ortho Clinical Diagnostics to Report First Quarter 2021 Results on May 5, 2021

Retrieved on: 
Wednesday, April 21, 2021
Medical tests, Ortho Clinical Diagnostics, Ortho, In vitro, Medicine

b"RARITAN, N.J., April 21, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world\xe2\x80\x99s largest pure-play in vitro diagnostics companies, today announced it will report results for its first quarter 2021 ended April 4, 2021, after the market close on May 5, 2021.\nOrtho Clinical Diagnostics will hold a conference call the same day at 5:00pm ET to discuss the results.

Key Points: 
  • b"RARITAN, N.J., April 21, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world\xe2\x80\x99s largest pure-play in vitro diagnostics companies, today announced it will report results for its first quarter 2021 ended April 4, 2021, after the market close on May 5, 2021.\nOrtho Clinical Diagnostics will hold a conference call the same day at 5:00pm ET to discuss the results.
  • Interested parties can access the call and accompanying presentation on the \xe2\x80\x9cInvestors\xe2\x80\x9d portion of the Company\xe2\x80\x99s website at https://ir.orthoclinicaldiagnostics.com/ .
  • Presentation materials will also be posted to the \xe2\x80\x9cInvestors\xe2\x80\x9d portion of the website at the time of the call.
  • Because Every Test is a LifeTM, Ortho provides hospitals, hospital networks, clinical laboratories and blood banks around the world with innovative technology and tools to ensure test results are fast, accurate, and reliable.

Medolife Rx Announces Pre-Clinical Results on Escozine Showing Synergistic Effect in Killing Cancer Cells When Combined With Chemotherapy Agents

Retrieved on: 
Tuesday, April 20, 2021
Oncology, Medicine, Clinical medicine, Health, Alternatives to animal testing, In vitro, Cancer, Chemotherapy

The Company considers this result very positive in that its lead drug candidate increased the effectiveness of chemotherapy in killing cancer cells and cancer cell lines.

Key Points: 
  • The Company considers this result very positive in that its lead drug candidate increased the effectiveness of chemotherapy in killing cancer cells and cancer cell lines.
  • For reference, cell lines are commonly used in in vitro model systems in many drug discovery research programs.
  • We are humbled to have worked with such a renowned research organization and could not be more excited by these results.
  • Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results.

Global Hepatitis B In-Vitro Diagnostics Tests Market Report 2021: Market Analysis and Forecast Model with COVID-19 Market Impact, 2015-2020 & 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 20, 2021
Health, Infectious diseases, Alternatives to animal testing, In vitro, Market analysis, Articles, Science

b'The "Hepatitis B Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact)" report has been added to ResearchAndMarkets.com\'s offering.\nHepatitis B Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.\nThe model discusses in detail the impact of COVID-19 on Hepatitis B Tests market for the year 2020 and beyond.

Key Points: 
  • b'The "Hepatitis B Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact)" report has been added to ResearchAndMarkets.com\'s offering.\nHepatitis B Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.\nThe model discusses in detail the impact of COVID-19 on Hepatitis B Tests market for the year 2020 and beyond.
  • To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available).
  • In addition, analysts provide unique country specific insights on the market.\nSWOT analysis for Hepatitis B Tests market.\nCompetitive dynamics insights and trends provided for Hepatitis B Tests market.\nDrive the understanding of the market by getting the veritable big picture including an overview of the healthcare system.
  • In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.\n'

World CRISPR Gene Detection and Diagnostic Market 2021-2025: Cost, Accuracy and Speed/ Economies of Multiplexing with Nucleic Acids / The New Agriculture / Pandemics and Pathogens / Health and Self

Retrieved on: 
Tuesday, April 20, 2021
Branches of biology, Biology, Life sciences, Biotechnology, Molecular biology, Genetic engineering, Biological engineering, Emerging technologies, CRISPR, Molecular diagnostics, COVID-19 testing, In vitro

Expect the big players to start taking notice.\nCRISPR is not just about changing genes.

Key Points: 
  • Expect the big players to start taking notice.\nCRISPR is not just about changing genes.
  • CRISPR identifies unique genetic material instantly, accurately and cheaply.
  • A new COVID test is already available.\nWill this disruptive technology change the world of In Vitro Diagnostics?
  • The two key trends of Point of Care Testing and Molecular Diagnostics are merging with spectacular success.

In Vitro Toxicology Testing Market Procurement Intelligence Report 2021-2025 with Q1, 2021 COVID-19 Impact Update| SpendEdge

Retrieved on: 
Tuesday, April 13, 2021
Alternatives to animal testing, Competition, Pricing, Toxicology, Negotiation, In vitro, Articles, Business

b"NEW YORK, April 13, 2021 /PRNewswire/ -- The In Vitro Toxicology Testingmarket will register an incremental spend of about USD 10.08 Billion, growing at a CAGR of 11.52% during the five-year forecast period.

Key Points: 
  • b"NEW YORK, April 13, 2021 /PRNewswire/ -- The In Vitro Toxicology Testingmarket will register an incremental spend of about USD 10.08 Billion, growing at a CAGR of 11.52% during the five-year forecast period.
  • A targeted strategic approach to In Vitro Toxicology Testingsourcing can unlock several opportunities for buyers.
  • This report also offers market impact and new opportunities created due to the COVID-19 pandemic.\nKey Highlights Offered in the Report:\nInformation on how to identify strategic and tactical negotiation levels that will help achieve the best prices.\nGain information on relevant pricing levels, detailed explanation on pros and cons of prevalent pricing models.\nMethods to help engage with the right suppliers and discover KPI's to evaluate incumbent suppliers.\nInsights into buyer strategies and tactical negotiation levers:\nSeveral strategic and tactical negotiation levers are explained in the report to help buyers achieve the best prices for the In Vitro Toxicology Testing market.
  • During the forecast period, the market expects a change of 2.00%-4.00%.\nExpected changes in price forecast and factors driving the current and future price changes.\nIdentify pricing models that offer the most rewarding opportunities.\nSome of the top In Vitro Toxicology Testing suppliers listed in this report:\nThis In Vitro Toxicology Testing procurement intelligence report has enlisted the top suppliers and their cost structures, SLA terms, best selection criteria, and negotiation strategies.\n"

Bold Therapeutics' BOLD-100 Effective In Vitro Against COVID-19 Variants

Retrieved on: 
Friday, April 16, 2021
Drug discovery, Pharmaceutical industry, COVID-19 pandemic in the United Kingdom, Lineage B.1.1.7, Preclinical development, In vitro, In vivo, Antiviral drug, Health sciences, Life sciences, Biology

New in vitro research completed by Bold Therapeutics\' collaborators at the University of British Columbia and Western University showed that BOLD-100 consistently reduced viral concentrations in multiple COVID-19 variants, including the highly prevalent B.1.1.7 variant originally identified in the UK (see Figure 1).

Key Points: 
  • New in vitro research completed by Bold Therapeutics\' collaborators at the University of British Columbia and Western University showed that BOLD-100 consistently reduced viral concentrations in multiple COVID-19 variants, including the highly prevalent B.1.1.7 variant originally identified in the UK (see Figure 1).
  • This work confirms and expands upon prior research demonstrating that BOLD-100 has strong antiviral activity against COVID-19 in a range of preclinical in vitro models.
  • Since that time, Bold Therapeutics has generated additional efficacy and safety data, including the aforementioned variant studies, and is currently completing in vivo studies of BOLD-100.
  • In parallel, Bold Therapeutics continues to enroll patients in its Phase 1b study of BOLD-100 in the treatment of advanced gastrointestinal cancers.

Global In Vitro Diagnostics Partnering Terms and Agreements Directory/Report 2014-2020

Retrieved on: 
Wednesday, March 31, 2021
Alternatives to animal testing, In vitro

DUBLIN, March 31, 2021 /PRNewswire/ -- The "Global In Vitro Diagnostics Partnering Terms and Agreements 2014-2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 31, 2021 /PRNewswire/ -- The "Global In Vitro Diagnostics Partnering Terms and Agreements 2014-2020" report has been added to ResearchAndMarkets.com's offering.
  • The Global In Vitro Diagnostics Partnering Terms and Agreements 2014-2020 report provides comprehensive access to available deals and contract documents for over 550 In Vitro Diagnostics deals.
  • The report takes the reader through a comprehensive review In Vitro Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering In Vitro Diagnostics partnering deals.
  • In Vitro Diagnostics Partnering Terms and Agreements includes:
    In Global In Vitro Diagnostics Partnering Terms and Agreements 2014-2020, the available deals are listed by:

Global Endotoxin Testing Industry (2021 to 2029) - Investment in Medical Devices Propelling Market Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 31, 2021
Professional services, Health, Medical devices, Finance, Articles, Economy, Business, Offshoring, Medical device, Compound annual growth rate, Outsourcing, In vitro

The global endotoxin testing market is developing significantly with an expected CAGR of 8.5% from 2019 - 2029.

Key Points: 
  • The global endotoxin testing market is developing significantly with an expected CAGR of 8.5% from 2019 - 2029.
  • The transition of medical device industry post the medical outsourcing has led to increased avenues in the developing economies as a result of increased and favorable public initiatives, regulations and increased market penetration for medical devices.
  • Apart from widening scope of medical devices there has been tremendous growth and advances in automation of data entry, data management and reporting.
  • Monocyte activation testing is an in vitro method, is a comparatively newer method in the industry.

CN Bio introduces the PhysioMimix™ OOC Multi-Organ Microphysiological System

Retrieved on: 
Wednesday, March 17, 2021
Biotechnology, Health, Clinical trials, Medical devices, Tissue engineering, Biotechnology, Microfluidics, Nanotechnology, Organ-on-a-chip, Alternatives to animal testing, OOC, Science and technology, In vitro, Life sciences, Biology

CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip (OOC), today announced the commercial launch of its new PhysioMimix OOC Multi-Organ MPS.

Key Points: 
  • CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip (OOC), today announced the commercial launch of its new PhysioMimix OOC Multi-Organ MPS.
  • CN Bios Multi-Organ MPS enables researchers to generate sophisticated in vitro models that better represent human inter-organ crosstalk effects compared to single-organ MPS, or animal models.
  • Prior to launch, the system has undergone extensive internal and external validation by the University of Pittsburgh, and by a major pharmaceutical company.
  • For future details on the PhysioMimix OOC range, now comprising the PhysioMimix Single-Organ and PhysioMimix Multi-Organ Systems, please visit: https://cn-bio.com/physiomimixooc/
    For a high-resolution image please contact Zyme Communications.